Sfoglia per RIVISTA
CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII
Collezione ASL Cuneo 2

  

Items : 3

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Rescigno P; Fornarini G; Buti S; Rebuzzi SE; Vignani F; Cavo A; Signori A; Banna GL; Tudini M; Malgeri A; Nole F; Prati G; Morelli F; Messina M; Di Napoli M; Atzori F; Prati V; Soraru M; Panni S; Mollica V; Pipitone S; Ricotta R; Fratino L; Catalano F; Milella M; Procopio G; Naglieri E; Masini C; Zucal PA; et alii...

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.

2024
ASL Cuneo 2

Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep

2023
ASL Cuneo 2
AOU Novara

Santoni M; Porta C; Bellmunt J; Battelli N; Sorgentoni G; Landmesser J; Rizzo A; Mollica V; Zabalza IO; Zgura A; Incorvaia L; Ansari J; Pinto A; Soares A; Nunes F; Maluf F; Morelli F; Mosca A; Zakopoulou R; Bisonni R; Manneh R; Santini D; Inman E; Herchenhorn D; Kanesvaran R; Caitano M; Milella M; Kopecky J; Martignetti A; et alii...